LALIT ANEJA MD NPI 1386989820

NPI Details

Lalit Aneja, MD is a medical oncology internal medicine in North Venice, FL with 18 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Lalit Aneja, MD NPI is 1386989820. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

5500 PINEBROOK RD STE 202
NORTH VENICE, FL
ZIP 34275-678
Phone: (941) 408-0500
Fax: (941) 496-8558

The NPI 1386989820 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Iron binding capacity (HCPCS:83550)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Folic acid level, serum (HCPCS:82746)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Protein measurement, serum (HCPCS:84165)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Magnesium level (HCPCS:83735)
• Blood test, clotting time (HCPCS:85610)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection of drug or substance into vein (HCPCS:96374)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Automated urinalysis test (HCPCS:81003)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Drawing of blood for a medical problem (HCPCS:99195)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Uric acid level, blood (HCPCS:84550)
• Testosterone (hormone) level, total (HCPCS:84403)
• Urinalysis, manual test (HCPCS:81002)
• Haptoglobin (serum protein) level (HCPCS:83010)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Alpha-fetoprotein (afp) level, serum (HCPCS:82105)
• Erythropoietin (protein) level (HCPCS:82668)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Hepatitis b core antibody measurement (HCPCS:86704)

The enumeration date for this NPI number is 12/10/2012 and was last updated on 10/23/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.